GlycoMimetics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows existing investors are selling shares, which can affect stock price and investor ownership stakes.
Regular financial updates help investors track company performance and understand how their money is being used.
Earnings reports reveal whether the company is making progress toward its business goals.
New capital helps fund drug development and operations; larger raises if underwriters exercise full option to $133.5 million.
Official document updating investors on offering details and company information incorporated by reference.
Shows how much money the company has available to spend on research, operations, and growth.
Official document updating investors on offering details and company information incorporated by reference.
Stocky reads GlycoMimetics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
GlycoMimetics, Inc.'s most recent tracked filing was a 424B3 on 30 Jul 2026: 19.6 million shares offered by selling securityholders.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.